Media headlines about Voyager Therapeutics (NASDAQ:VYGR) have trended somewhat positive this week, according to Accern Sentiment. The research firm identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Voyager Therapeutics earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned news stories about the company an impact score of 45.185448570808 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Here are some of the media headlines that may have effected Accern Sentiment’s analysis:

How to Become a New Pot Stock Millionaire

NASDAQ VYGR traded up $0.30 during trading hours on Tuesday, reaching $18.98. The company’s stock had a trading volume of 80,192 shares, compared to its average volume of 429,466. The stock has a market capitalization of $603.88, a price-to-earnings ratio of -7.17 and a beta of 2.98. Voyager Therapeutics has a 1-year low of $8.10 and a 1-year high of $31.91.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings data on Wednesday, March 14th. The company reported ($0.40) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.72) by $0.32. Voyager Therapeutics had a negative return on equity of 63.18% and a negative net margin of 697.03%. The company had revenue of $6.35 million during the quarter, compared to analyst estimates of $5.81 million. equities analysts anticipate that Voyager Therapeutics will post -2.54 EPS for the current fiscal year.

A number of equities analysts recently weighed in on the company. BidaskClub raised Voyager Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, April 12th. Canaccord Genuity set a $35.00 price target on Voyager Therapeutics and gave the stock a “buy” rating in a report on Monday, April 9th. Morgan Stanley assumed coverage on Voyager Therapeutics in a report on Friday, February 2nd. They issued an “overweight” rating for the company. ValuEngine raised Voyager Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, April 2nd. Finally, Zacks Investment Research cut Voyager Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, January 25th. Five equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $29.73.

In other Voyager Therapeutics news, insider Bernard Ravina sold 2,451 shares of the business’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $18.24, for a total transaction of $44,706.24. Following the completion of the sale, the insider now directly owns 4,902 shares in the company, valued at approximately $89,412.48. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Jane Henderson sold 17,316 shares of the business’s stock in a transaction that occurred on Monday, March 19th. The stock was sold at an average price of $22.11, for a total value of $382,856.76. Following the sale, the chief financial officer now owns 15,416 shares of the company’s stock, valued at $340,847.76. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 66,908 shares of company stock valued at $1,574,258. 8.00% of the stock is owned by company insiders.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.dailypolitical.com/2018/04/17/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-voyager-therapeutics-vygr-stock-price.html.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.

Insider Buying and Selling by Quarter for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.